Skip to main content
. Author manuscript; available in PMC: 2006 Sep 1.
Published in final edited form as: Clin Cancer Res. 2005 Sep 1;11(17):6342–6351. doi: 10.1158/1078-0432.CCR-05-0596

Table 1.

Binding of human mesothelin peptides and analog peptides to HLA-A2 molecules

Experiment 1: Analysis of native human mesothelin peptide to HLA-A2 molecules
Peptide Amino acid position in mesothelin Sequence T2 bindinga
P21 21-29 FLLFSLGWV 241 (1.5)
P547 547-556 KLLGPHVEGL 407 (2.6)
MUC-1 (positive control) NA ALWGQDVTSV 422 (2.7)
CAP-7 (negative control) NA HLFGYSWYK 152
Experiment 2: Analysis of analog peptides
Mesothelin agonist peptides derived from P547 Designation Peptide sequence T2 bindinga
P547 (native) P547 KLLGPHVEGL 226 (1.5)
554L P547-1 KLLGPHVLGL 180 (1.2)
554L/556V P547-2 KLLGPHVLGV 289 (2.0)
548M/554L/556V P547-3 KMLGPHVLGV 368 (2.6)
548I/554L/556V P547-4 KILGPHVLGV 342 (2.3)
548M/554L P547-5 KMLGPHVLGL 132 (0.9)
548I/554L P547-6 KILGPHVLGL 185 (1.3)
547Y/554L/556V P547-7 YLLGPHVLGV 234 (1.6)
547Y/554L P547-8 YLLGPHVLGL 161 (1.1)
MUC-1 peptide (positive control) ALWGQDVTSV 390 (2.7)
CAP-7 (negative control) HLFGYSWYK 144
a

Results are expressed in mean fluorescence intensity (MFI). MUC-1 peptide is an HLA-A2 binding peptide and CAP-7 is an HLA-A3 binding CEA peptide.

NA, not applicable.

Peptides were used at a concentration of 25 μg/ml. Values in parentheses are fold increases as compared with the negative control. Amino acid sequences of the parental P547 peptide (amino acid position 547-556 of mesothelin) and analog peptides. Amino acids are shown by the single-letter code. Substitution amino acids are indicated in bold italic and underlined.